Articles Archives

Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break

As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.

Read More

Cryoport Systems with ISCT on Why Early-Phase Development is Starting to Strain

As advanced therapy programs move faster toward first-in-human (FIH), the pressure isn’t just showing up at commercial scale. It’s appearing much earlier than many teams expect.   A recent article Cryoport Systems published with ISCT takes a closer look at that shift, highlighting why execution (not feasibility) is increasingly becoming the constraint in early development.

Read More

Top 10 Industry Predictions for 2025

Cryoport Systems’ CEO, Mark Sawicki, provides a comprehensive analysis into the challenges and growth opportunities shaping the CGT industry.

Read More